🇺🇸 CG Oncology, Inc.CGON

Company Update Form 8-K 16-11-2026 08:15:21 EST

Subject: 8-K Items 7.01, 8.01, 9.01

Overview: Announced positive topline PIVOT-006 Phase 3 results for cretostimogene, showing a 68% reduction in recurrence risk for intermediate-risk and high-grade Ta NMIBC.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest